US Medicaid programs say cost a key factor for weight-loss drug coverage, survey finds
Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their ...
UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use
Eli Lilly's treatment for early Alzheimer's was deemed too expensive for wide use by UK's cost-effectiveness body on ...
KSAT33m
UK regulator approves second Alzheimer's drug in months but government won't pay for it
Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after ...
WJCL on MSN39m
Maggie Lilly causing a buzz with her 'Party of Hive' granola
Maggie Lilly is creating a buzz with her Party of Hive granola."It's just amazing," said Lilly. "The journey to get to this point has been life changing. Every step you take is leading you somewhere ...
Grays Harbor Daily News44m
Aberdeen sweeps W.F. West on Senior Night
Playing in front of a Senior Night crowd in the midst of its best season in decades, the Bobcats (9-3 overall, 6-1 1A ...
ENDPOINTS NEWS48m
Lil­ly’s Alzheimer’s drug green­lit by UK, but price watch­dog says it's too cost­ly
The UK medicines authority approved Eli Lilly’s Alzheimer’s drug Kisunla on Wednesday, making it the third major market to ...
The Financial Express49m
UK regulator approves Lilly’s Alzheimer’s drug but ‘too expensive’ for wider use
Donanemab, given as an infusion every four weeks, has shown to slow down cognitive decline by 4-7 months in clinical studies.